From narrowly targeted biologic investigations to population research deploying an innovative cluster-randomized approach, this group evaluates targeted and non-targeted outcomes from vaccines from bench to the field across the age span.
Vaccines and Primary Prevention Research Group
Angela M. Bengtson, PhD
Assistant Professor of Epidemiology
Dr. Bengtson's research focuses on improving the health of HIV-infected women and their children during the perinatal period. Her work explores the impact of HIV drugs on pregnancy outcomes, investigates novel strategies to measure and support ongoing engagement in HIV care, and addresses common comorbid conditions with HIV during pregnancy, including obesity and perinatal depression.
David D. Dore, PharmD, PhD
Adjunct Assistant Professor of Health Services, Policy and Practice
Dr. Dore is a pharmacoepidemiologist whose main research interests are in the study of drug effects, with applications to drug safety and comparative effectiveness research. His clinical areas of interest are diabetes mellitus, cardiovascular disease, aging, and mental health.
Stefan Gravenstein, MD, MPH
Professor of Health Services, Policy and Practice, Professor of Medicine
Dr. Gravenstein’s research interests include quality improvement in healthcare, influenza in elderly people, immune senescence, and vaccine response. He also has specific interests in the culture of care, antimicrobial stewardship, and how to improve care across care transitions.
Timothy P. Flanigan, MD
Professor of Medicine, Professor of Health Services, Policy and Practice
Dr. Flanigan has spearheaded both clinical care and clinical research programs for improved HIV treatment among marginalized communities. His research focuses on HIV care in underserved communities, particularly substance abusers, women, inner-city communities and incarcerated men and women.
Michelle A. Lally, MD, MSc
Associate Professor of Medicine, Director of Brown AIDS Center (CFAR), Director of Brown University AIDS Program (BRUNAP), Associate Professor of Health Services, Policy& Practice
Dr. Lally’s research focus includes 1) HIV Prevention among Youth: HIV Vaccination & Pre-exposure Prophylaxis (PrEP), 2) HIV Testing: rapid testing for Acute HIV, HIV testing bundled with other services (HPV vaccination), and 3) Implementation Research: HIV prevention through community engagement and policy changes; youth vaccination at schools.
Vincent Mor, PhD
Florence Pirce Grant University Professor, Professor of Health Services, Policy and Practice
Dr. Mor’s research focuses on the organizational and health care delivery system factors associated with variation in use of health services, and outcomes experienced by frail and chronically ill persons. His areas of study include: the quality of nursing home care, Medicare funding for post-acute care, the determinants of hospitalization, disease management for cancer patients and age and racial discrimination in health care treatments.
Orestis Panagiotou, MD, PhD
Assistant Professor of Health Services, Policy and Practice (Research)
Dr. Panagiotou’s research interests include comparative effectiveness and safety research and risk prediction, particularly in the context of routinely-collected health data. Dr. Panagiotou works on both applied and methodological problems in the following research areas: 1) delivery of cancer care and outcomes thereof across the cancer continuum from screening to treatment, 2) quality of care with an emphasis on low-value care, 3) evidence synthesis, meta-analysis, and replicability of clinical trials, 4) computational health services research
David A. Savitz, PhD
Associate Dean for Research, Professor of Epidemiology, Professor of Obstetrics & Gynecology, Professor of Pediatrics
Dr. Savitz's research is focused on reproductive and environmental epidemiology. He has conducted studies on the causes of adverse pregnancy outcome, including miscarriage and preterm birth, as well as pregnancy complications, birth defects, and child health problems. His environmental interests include a wide range of chemical and physical exposures, including perfluorinated chemicals, pesticides, drinking water treatment by-products, and non-ionizing radiation.
Theresa I. Shireman, PhD
Professor of Health Services, Policy and Practice
Dr. Shireman specializes in pharmacoepidemiology and health economic evaluations. Her significant research achievements include contributions to understanding how medications are used and to what effect in people who are on chronic dialysis, development of a novel methodology to tracking medication exposure over time, development of a bleeding risk prediction model for warfarin in older adult patients with atrial fibrillation, and health economic evaluations of expensive therapeutic agents.
Patrick M. Vivier
Professor of Health Services, Policy and Practice, Professor of Pediatrics, Professor of Emergency Medicine
Dr. Vivier's work focuses on the health status and health services utilization of low-income families. His current research areas include lead poisoning, injury, asthma, emergency department use, and early life factors that impact health as well as flourishing, including a focus on predictors of third grade reading proficiency.
Stratified Cluster Random Assignment Trial FluAd
Principal Investigator: Dr. Vincent Mor
Funding: Insight Therapeutics, LLC
Adjuvanted Influenza Vaccination and Morbidity and Mortality in U.S. Nursing Homes: Assessment of Vaccine Selection and Outcomes for the Follow-on Study Year.
Principal Investigator: Dr. Stefan Gravenstein; Co-investigator: Dr. Vincent Mor
Funding: Insight Therapeutics, LLC
Bengtson A. M., Sanfilippo A. M., Hughes B, Savitz D. A. Maternal immunization to improve the health of HIV-exposed infants: a review of the current evidence. In press, The Lancet Infectious Diseases.
Bonney, L. E., Lally, M., Williams, D. R., Stein, M., & Flanigan, T. (2006). Where to begin human papillomavirus vaccination? The Lancet. Infectious Diseases, 6(7), 389–390. https://doi.org/10.1016/S1473-3099(06)70501-1
De Groot, A. S., Bishop, E. A., Khan, B., Lally, M., Marcon, L., Franco, J., … Martin, W. (2004). Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine. Methods (San Diego, Calif.), 34(4), 476–487. https://doi.org/10.1016/j.ymeth.2004.06.003
Dore, D. D., Turnbull, B. R., & Seeger, J. D. (2012). Vaccine discontinuation and switching following regulatory interventions in response to rotavirus vaccine contamination with porcine circovirus DNA fragments. Pharmacoepidemiology and Drug Safety, 21(4), 415–419. https://doi.org/10.1002/pds.3217
Fell, D. B., Bhutta, Z. A., Hutcheon, J. A., Karron, R. A., Knight, M., Kramer, M. S., … Savitz, D. A. (2017). Report of the WHO technical consultation on the effect of maternal influenza and influenza vaccination on the developing fetus: Montreal, Canada, September 30-October 1, 2015. Vaccine, 35(18), 2279–2287. https://doi.org/10.1016/j.vaccine.2017.03.056
Gravenstein, S., Davidson, H. E., Han, L. F., Ogarek, J. A., Dahal, R., Gozalo, P. L., … Mor, V. (2018). Feasibility of a cluster-randomized influenza vaccination trial in U.S. nursing homes: Lessons learned. Human Vaccines & Immunotherapeutics, 14(3), 736–743. https://doi.org/10.1080/21645515.2017.1398872
Gravenstein, S., Davidson, H. E., Taljaard, M., Ogarek, J., Gozalo, P., Han, L., & Mor, V. (2017). Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. The Lancet Respiratory Medicine, 5(9), 738–746. https://doi.org/10.1016/S2213-2600(17)30235-7
Gravenstein, S., Davidson, H. E., Taljaard, M., Ogarek, J., Gozalo, P., Han, L., & Mor, V. (2017). Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. The Lancet. Respiratory Medicine, 5(9), 738–746. https://doi.org/10.1016/S2213-2600(17)30235-7
Gravenstein, S., Dahal, R., Gozalo, P. L., Davidson, H. E., Han, L. F., Taljaard, M., & Mor, V. (2016). A cluster randomized controlled trial comparing relative effectiveness of two licensed influenza vaccines in US nursing homes: Design and rationale. Clinical Trials (London, England), 13(3), 264–274. https://doi.org/10.1177/1740774515625976
Gravenstein, S., Taljaard, M., Gozalo, P., Dahal, R., Davidson, H. E., Han, L., … Mor, V. (2015). Relative Effect of High-Dose Influenza Vaccination on Hospitalizations of Older Adults in United States Nursing Homes: Results From a Cluster-Randomized Controlled Trial. Open Forum Infectious Diseases, 2(Suppl 1). https://doi.org/10.1093/ofid/ofv130.08
Harro, C. D., Robertson, M. N., Lally, M. A., O’Neill, L. D., Edupuganti, S., Goepfert, P. A., … Merck V520-007/012 Study Teams. (2009). Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Research and Human Retroviruses, 25(1), 103–114. https://doi.org/10.1089/aid.2008.0212
Hoffman, V., Everage, N. J., Quinlan, S. C., Skerry, K., Esposito, D., Praet, N., … Dore, D. D. (2016). Validation of current procedural terminology codes for rotavirus vaccination among infants in two commercially insured US populations. Pharmacoepidemiology and Drug Safety, 25(12), 1465–1469. https://doi.org/10.1002/pds.4085
Kozlowski, P. A., Cu-Uvin, S., Neutra, M. R., & Flanigan, T. P. (1999). Mucosal vaccination strategies for women. The Journal of Infectious Diseases, 179 Suppl 3, S493-498. https://doi.org/10.1086/314810
Lally, M., Goldsworthy, R., Sarr, M., Kahn, J., Brown, L., Peralta, L., & Zimet, G. (2014). Evaluation of an intervention among adolescents to reduce preventive misconception in HIV vaccine clinical trials. The Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine, 55(2), 254–259. https://doi.org/10.1016/j.jadohealth.2014.01.006
Lally, M., Gaitanis, M., Vallabhaneni, S., Reinert, S., Mayer, K., Zimet, G., & Rich, J. (2006). Willingness to receive an HIV vaccine among incarcerated persons. Preventive Medicine, 43(5), 402–405. https://doi.org/10.1016/j.ypmed.2006.06.012
Lally, M. A., Montstream-Quas, S. A., Tanaka, S., Tedeschi, S. K., & Morrow, K. M. (2008). A qualitative study among injection drug using women in Rhode Island: attitudes toward testing, treatment, and vaccination for hepatitis and HIV. AIDS Patient Care and STDs, 22(1), 53–64. https://doi.org/10.1089/apc.2006.0206
Ott, M. A., Alexander, A. B., Lally, M., Steever, J. B., Zimet, G. D., & Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions. (2013). Preventive misconception and adolescents’ knowledge about HIV vaccine trials. Journal of Medical Ethics, 39(12), 765–771. https://doi.org/10.1136/medethics-2012-100821
Panagiotou, O. A., Befano, B. L., Gonzalez, P., Rodríguez, A. C., Herrero, R., Schiller, J. T., … Costa Rica HPV Vaccine Trial (CVT) Group (see end of manuscript for full list of investigators). (2015). Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. BMJ (Clinical Research Ed.), 351, h4358. https://doi.org/10.1136/bmj.h4358
Quirk, E. K., Mogg, R., Brown, D. D., Lally, M. A., Mehrotra, D. V., DiNubile, M. J., & Robertson, M. N. (2008). HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 47(12), 1593–1599. https://doi.org/10.1086/593313
Rich, J. D., Ching, C. G., Lally, M. A., Gaitanis, M. M., Schwartzapfel, B., Charuvastra, A., … Flanigan, T. P. (2003). A review of the case for hepatitis B vaccination of high-risk adults. The American Journal of Medicine, 114(4), 316–318. PMID: 12681460
Rudy, B. J., Kapogiannis, B. G., Lally, M. A., Gray, G. E., Bekker, L.-G., Krogstad, P., & McGowan, I. (2010). Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials. Journal of Acquired Immune Deficiency Syndromes (1999), 54 Suppl 1, S31-42. https://doi.org/10.1097/QAI.0b013e3181e3a922
Savitz, D. A., Fell, D. B., Ortiz, J. R., & Bhat, N. (2015). Does influenza vaccination improve pregnancy outcome? Methodological issues and research needs. Vaccine, 33(47), 6430–6435. https://doi.org/10.1016/j.vaccine.2015.08.041
Shireman, T. I., Ogarek, J., Gozalo, P., Zhang, T., Mor, V., Davidson, H. E., … Gravenstein, S. (2019). Cost Benefit of High-Dose vs Standard-Dose Influenza Vaccine in a Long-Term Care Population During an A/H1N1-Predominant Influenza Season. Journal of the American Medical Directors Association. https://doi.org/10.1016/j.jamda.2018.12.003
Spearman, P., Lally, M. A., Elizaga, M., Montefiori, D., Tomaras, G. D., McElrath, M. J., … HIV Vaccine Trials Network of NIAID. (2011). A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. The Journal of Infectious Diseases, 203(8), 1165–1173. https://doi.org/10.1093/infdis/jiq175
Vivier, P. M., Alario, A. J., Simon, P., Flanagan, P., O’Haire, C., & Peter, G. (1999). Immunization status of children enrolled in a hospital-based medicaid managed care practice: the importance of the timing of vaccine administration. The Pediatric Infectious Disease Journal, 18(9), 783–788. PMID: 10493338
Vivier, P. M., Alario, A. J., Peter, G., Leddy, T., Simon, P., & Mor, V. (2001). An analysis of the immunization status of preschool children enrolled in a statewide Medicaid managed care program. The Journal of Pediatrics, 139(5), 624–629. https://doi.org/10.1067/mpd.2001.118884
Master of Science
Perez, Ashley Elizabeth, "Disparities in human papillomavirus vaccination initiation and completion by nativity status among U.S. adults" (2017). Public Health Theses and Dissertations. Brown Digital Repository. Brown University Library. https://doi.org/10.7301/Z0QV3K0C